- Raised $500k grant, Dec 2023
- Raised Series A led by Horizons Ventures, Oct 2014
- Raised Seed round led by AMIT-Technion ( The Alfred Mann Institute), Oct 2012
About
Accellta is an Israeli biotechnology company founded in 2012, specializing in scalable cell culture innovation. The company develops and markets solutions for the mass production of human embryonic and induced pluripotent stem cells, progenitors, and differentiated cells for applications in biopharma, regenerative medicine, drug discovery, and sustainable food production. Accellta's proprietary 3D suspension culture platform enables high-quality cell production without microcarriers or scaffolds, utilizing xeno-free and chemically defined media. Located in the Technion in Haifa, Israel, Accellta is committed to advancing cell culture technology and providing custom-made solutions for industrial-scale cell banking and clinical batch production. They are also actively involved in FoodTech, developing cultured dairy fat. Accellta is a company founded and managed primarily by women.
Funding history · 3 rounds · $500K total
Headcount over time
Q&A
- What is Accellta's primary focus?
- Accellta specializes in the industrial-scale production of embryonic and induced pluripotent stem cells, progenitors, and differentiated cells for applications in cell banking, drug discovery, regenerative medicine, and scientific research.
- How does Accellta differentiate its cell culturing technology?
- Accellta utilizes 3D carrier-free suspension systems under feeder-free, adherent-free, and xeno-free conditions to optimize production efficiency and reduce costs while maintaining consistent quality.
- When was Accellta founded?
- Accellta was founded in November 2012.
- What is the current employee count for Accellta?
- Accellta has 17 employees, falling within the 11-50 employee bucket.
- What was Accellta's most recent funding event?
- In January 2024, Accellta received a Grant of $500,000 from the Israel Innovation Authority.
- What is Accellta's total amount raised to date?
- Accellta has raised a total of $500,000 USD.
- Does Accellta hold any patents?
- Yes, Accellta holds patents covering media formulations and pluripotent stem cell culturing techniques.
- What is the primary sector Accellta operates in?
- Accellta's primary sector is Health Tech & Life Sciences.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | accellta.com |
|---|---|
| linkedin.com/company/10379250 | |
| Wikidata | wikidata.org/wiki/Q52148786 |
Identifiers & details
| Legal name | Accellta Ltd. |
|---|---|
| Founded | 2012-11 |
| Employees (exact) | 18 |
| Wikidata QID | Q52148786 |
Radar intelligence
Patents
| EPO | 6 |
|---|
Web history (Wayback)
| Domain | accellta.com |
|---|
Wikidata
| QID | Q52148786 |
|---|
Certificate / subdomain footprint
| Subdomains | 9 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514840446 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2012-11-20 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 1 — annual_report (1) |
| Registered address | שד שיקגו 1 חיפה |
Recent registry events
| Date | Event |
|---|---|
| 2026-02-11 | דו~ח שנתי |